Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Angela M. Minassian, Sue Ann Costa Clemens et al.|The Lancet|2020Cited by 5k
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Angela M. Minassian, Sue Ann Costa Clemens et al.|The Lancet|2021Cited by 1.2k
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studySue Ann Costa Clemens, Laiana Januse de Arruda Cordeiro Matos, Lily Yin Weckx et al.|The Lancet|2022Cited by 467
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) VaccineMerryn Voysey, Alastair McGregor, Sue Ann Costa Clemens et al.|SSRN Electronic Journal|2021Cited by 31
Identification of Serologic Markers for School-Aged Children With Congenital Rubella SyndromeMarisa M rcia Mussi Pinhata, Jaime Olbrich Neto, Maria C. Bevilacqua et al.|The Journal of Infectious Diseases|2014Cited by 17